TY - JOUR
T1 - Scheduling of testing tasks and resource planning in new product development using stochastic programming
AU - Colvin, Matthew
AU - Maravelias, Christos T.
N1 - Funding Information:
The authors would like to acknowledge financial support from the National Science Foundation under Grant CTS-0547443. The authors would also like to thank Dr. Vassilis Lefkaditis from SDG Life Sciences, a Unit of IMS, for fruitful discussions on the testing of pharmaceuticals.
PY - 2009/5/21
Y1 - 2009/5/21
N2 - Testing is a crucial step in new product development in many industrial sectors, from microelectronics to the automotive industry. In the pharmaceutical sector, specifically, candidate drugs have to undergo clinical trials, a process that takes 2-4 years and costs hundreds of millions of dollars. In this paper we are concerned with the scheduling of clinical trials and the planning of the resources necessary to carry these trials out. We present a stochastic programming (SP) framework that addresses the two problems simultaneously. To address large problems we develop a number of results and methods. First, we exploit the structure of the problem to reduce the number of pairs of scenarios for which non-anticipativity has to be enforced, and the number of binary variables. Second, we develop a finite-horizon approximation that allows us to formulate problems using fewer stages without compromising the quality of the solution. Third, we take advantage of the sequential nature of the testing process to develop a smaller but tighter mixed-integer programming (MIP) formulation; we show that a relaxation of this formulation can be used to obtain feasible and most often optimal solutions over the stages of interest. Finally, we develop a rolling-horizon-based approach, where the decisions of the relaxed problem are used over few early periods determining how and when uncertainty will be realized, and a new problem is formulated and solved as we move forward in time.
AB - Testing is a crucial step in new product development in many industrial sectors, from microelectronics to the automotive industry. In the pharmaceutical sector, specifically, candidate drugs have to undergo clinical trials, a process that takes 2-4 years and costs hundreds of millions of dollars. In this paper we are concerned with the scheduling of clinical trials and the planning of the resources necessary to carry these trials out. We present a stochastic programming (SP) framework that addresses the two problems simultaneously. To address large problems we develop a number of results and methods. First, we exploit the structure of the problem to reduce the number of pairs of scenarios for which non-anticipativity has to be enforced, and the number of binary variables. Second, we develop a finite-horizon approximation that allows us to formulate problems using fewer stages without compromising the quality of the solution. Third, we take advantage of the sequential nature of the testing process to develop a smaller but tighter mixed-integer programming (MIP) formulation; we show that a relaxation of this formulation can be used to obtain feasible and most often optimal solutions over the stages of interest. Finally, we develop a rolling-horizon-based approach, where the decisions of the relaxed problem are used over few early periods determining how and when uncertainty will be realized, and a new problem is formulated and solved as we move forward in time.
KW - Mixed-integer programming
KW - New product development
KW - Optimization under uncertainty
KW - Stochastic programming
UR - http://www.scopus.com/inward/record.url?scp=63749092674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63749092674&partnerID=8YFLogxK
U2 - 10.1016/j.compchemeng.2008.09.010
DO - 10.1016/j.compchemeng.2008.09.010
M3 - Article
AN - SCOPUS:63749092674
SN - 0098-1354
VL - 33
SP - 964
EP - 976
JO - Computers and Chemical Engineering
JF - Computers and Chemical Engineering
IS - 5
ER -